Sutro strengthens its immuno-oncology pipeline with two new ADCs

In June, Sutro received a $140m payment from Blackstone Life Sciences as part of the Vaxcyte product licensing agreement.

Aug 12, 2023 - 20:00

Sutro strengthens its immuno-oncology pipeline with two new ADCs

In June, Sutro received a $140m payment from Blackstone Life Sciences as part of the Vaxcyte product licensing agreement.

Read the original article

Tags:

Previous Article

Clinigen clears out cancer therapies in line with latest growth strategy

Signal: Wave of layoffs in medical start-ups exposes underlying vulnerability

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

FDA grants breakthrough therapy status for Nuvalent’s NVL-655

FDA grants breakthrough therapy status for Nuvalent’s N...

May 19, 2024

STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax

STAT+: Pharmalittle: Pharma moves closer to a pricing d...

Oct 24, 2023

Insights from ISPOR Europe 2023: Copenhagen

Insights from ISPOR Europe 2023: Copenhagen

Dec 14, 2023